Global study of an mRNA vaccine to prevent COVID-19

A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 in Participants Aged 18 Years and Older

This study is testing a new mRNA vaccine to see if it can help prevent COVID-19 in adults aged 18 and older.

Quick facts

• Phase: PHASE3
• Study type: Interventional
• Enrollment: 34000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: AIM Vaccine Co., Ltd. (industry)
• Drugs / interventions: prednisone
• Locations: 1 site (Siaya)
• Trial ID: NCT05682638 on ClinicalTrials.gov

What this trial studies

This is a global, multi-center, randomized, blinded, placebo-controlled Phase 3 clinical study evaluating the efficacy, safety, and immunogenicity of the SARS-CoV-2 mRNA vaccine (LVRNA009) in adults aged 18 years and older. Participants will receive either the vaccine or a placebo and will be monitored for their immune response and any adverse effects. The study aims to provide robust data on the vaccine's ability to prevent COVID-19 infection.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 years and older who are willing to comply with study requirements.

Not a fit: Patients who are not able to understand the informed consent process or those who cannot comply with study requirements may not benefit from this study.

Why it matters

Potential benefit: If successful, this vaccine could significantly reduce the incidence of COVID-19 among vaccinated individuals.

How similar studies have performed: Other studies of mRNA vaccines have shown significant success in preventing COVID-19, indicating a promising approach.

Eligibility criteria

Inclusion Criteria:

1. Adults aged 18 years and older.
2. Understand the content of the Informed Consent Form (ICF), and voluntarily sign the ICF (If the participant is unable to sign the ICF on his/her own due to illiteracy, an impartial witness is needed).
3. Participants who are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures.
4. Female participants of childbearing potential or partners of male participants:

   voluntarily agree to use effective contraception with their partners prior to the first vaccination and must agree to continue such precautions during the study until 3 months after full vaccination (including the initial set of vaccination and crossover set of vaccination). \[Effective contraception includes oral contraceptives, injectable or implantable contraception, extended-release topical contraceptives, hormonal patches, intrauterine devices (IUDs), sterilization, abstinence, condoms (for male), diaphragms, cervical caps, etc.\].
5. For female participants: without childbearing potential (amenorrhea for at least 1 year or documented surgical sterilization) or have used effective contraception with a negative pregnancy test before each vaccination in this study.
6. On the day of 1st dose of vaccination and 24 hours prior to vaccination, axillary temperatures \<37.3°C/99.1°F.
7. Healthy participants or participants with mild underlying disease \[in a stable state without exacerbation (no admission to hospital or no major adjustment to treatment regimen, etc.) for at least 3 months prior to enrollment in this study\].

Exclusion Criteria:

1. History of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), or other coronavirus infections.
2. Individuals using prescription medications for prophylaxis or treatment of SARS-CoV-2 (including vaccination of licensed COVID-19 vaccines).
3. History of a previous laboratory-confirmed diagnosis of SARS-CoV-2 infection or COVID-19.
4. History of allergy to any component of the study vaccine or history of severe allergic reaction to vaccine or drug (including but not limited to anaphylaxis, allergic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, or localized allergic necrosis (Arthus reaction)).
5. Positive nucleic acid for SARS-CoV-2 in nasopharyngeal/oropharyngeal swab specimens.
6. Positive HIV test results.
7. A history or family history of convulsions, epilepsy, encephalopathy and psychosis.
8. Malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period.
9. Asplenia or functional asplenia, complete or partial splenectomy from any cause.
10. Prolonged (defined as more than 14 days) use of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids, ≥20 mg/d prednisone or equivalent; however, inhaled and topical steroids are permitted) within 6 months prior to the 1st dose of investigational vaccine.
11. Any other licensed vaccines given within 28 days prior to the study vaccination, or planned administration of vaccine(s) within 28 days after the 2nd dose in the blinded crossover vaccination.
12. Have received immunoglobulin or other blood products within 3 months prior to enrollment or plan to receive them during the study period.
13. Blood donation or blood loss ≥ 450 mL within 1 month prior to enrollment or planned to donate blood during the study period.
14. Participants who have received any other investigational product within 1 month prior to enrollment or intent to participate in another clinical study at any time during the conduct of this study.
15. Women who are pregnant or breastfeeding.
16. Participants deemed unsuitable for participation in this study based on the investigator's assessment.

Where this trial is running

Siaya

• KEMRI CRDR Research Annex, Siaya Country Referral Hospital — Siaya, Kenya (RECRUITING)

Study contacts

• Study coordinator: Videlis Nduba, PHD

Conditions: SARS-CoV-2, mRNA, Prevention